Revance Therapeutics, Inc. Form 8-A12B February 04, 2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

Revance Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State of incorporation or organization)

77-0551645 (I.R.S. Employer Identification no.)

7555 Gateway Boulevard

Newark, CA 94560 (Address of principal executive offices) (Zip code) Securities to be registered pursuant to Section 12(b) of the Act:

Edgar Filing: Revance Therapeutics, Inc. - Form 8-A12B

Title of each class

to be so registered Common Stock, \$0.001 par value per share

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x

Name of exchange on which

each class is to be registered The NASDAQ Stock Market LLC

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange

Act and is effective pursuant to General

Instruction A.(d), check the following box.

Securities Act registration statement file number to which the form relates: 333-193154

Securities to be registered pursuant to Section 12(g) of the Act: None

Item 1. Description of Registrant s Securities to be Registered.

A description of the common stock, \$0.001 par value per share, of Revance Therapeutics, Inc., a Delaware corporation (the Registrant), to be registered hereunder is contained in the section entitled Description of Capital Stock in the prospectus included in the Registrant s Registration Statement of Form S-1 (File No. 333-193154), initially filed with the Securities and Exchange Commission (the Commission) on December 31, 2013, as amended from time to time (the Registration Statement), and is incorporated herein by reference. Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.

Item 2. Exhibits.

Under the instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on the NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

REVANCE THERAPEUTICS, INC.

Date: February 3, 2014 By: /s/ L. Daniel Browne

L. Daniel Browne

President and Chief Executive Officer